Compare
Monte Rosa Therapeutics, Inc. vs Atara Biotherapeutics, Inc. vs ImmunityBio, Inc. vs Beam Therapeutics Inc.
| Latest fiscal year | Monte Rosa Therapeutics, Inc. GLUE | Atara Biotherapeutics, Inc. ATRA | ImmunityBio, Inc. IBRX | Beam Therapeutics Inc. BEAM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $123.67M | $120.77M | $113.29M | $139.74M |
| Revenue growth (YoY) | +63.5% | -6.3% | +668.3% | +120.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -43.8% | 29.7% | -226.0% | -274.6% |
| Net margin | -31.2% | 27.1% | -310.2% | -57.2% |
| Net income | -$38.63M | $32.69M | -$351.40M | -$79.99M |
| EPS (Diluted) | n/a | $2.57 | -$0.38 | -$0.81 |
| Operating cash flow | -$22.80M | -$50.94M | -$304.94M | -$345.10M |
| Free cash flow | -$27.50M | -$50.94M | -$308.78M | -$360.05M |
| Cash & equivalents | $129.88M | $8.48M | $88.33M | $294.94M |
| Total assets | $448.66M | $20.23M | $501.90M | $1.48B |
| Total liabilities | $215.60M | $58.74M | $1.00B | $242.82M |
| Shareholders' equity | $233.06M | -$38.50M | -$500.47M | $1.24B |
| Return on year-end equity | -16.6% | n/a | n/a | -6.5% |
| Shares outstanding | 65.54M | 7.32M | 1.01B | 101.75M |
Revenue, most recent five fiscal years
| Fiscal year | Monte Rosa Therapeutics, Inc. | Atara Biotherapeutics, Inc. | ImmunityBio, Inc. | Beam Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $123.67M Ended 2025-12-31 | $120.77M Ended 2025-12-31 | $113.29M Ended 2025-12-31 | $139.74M Ended 2025-12-31 |
| 1 year earlier | $75.62M Ended 2024-12-31 | $128.94M Ended 2024-12-31 | $14.74M Ended 2024-12-31 | $63.52M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $8.57M Ended 2023-12-31 | $622.0K Ended 2023-12-31 | $377.71M Ended 2023-12-31 |
| 3 years earlier | n/a | $63.57M Ended 2022-12-31 | $240.0K Ended 2022-12-31 | $60.92M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $934.0K Ended 2021-12-31 | $51.84M Ended 2021-12-31 |